International Journal of Hepatology / 2017 / Article / Tab 2

Research Article

Shorter Leukocyte Telomere Length in Relation to Presumed Nonalcoholic Fatty Liver Disease in Mexican-American Men in NHANES 1999–2002

Table 2

Logistic regression of telomere length on elevated ALT, age 20 and older, and other indicators of suspected nonalcoholic fatty liver disease, NHANES 1999–2002.

Model 1, unadjustedModel 2,
demographic
Model 3, demographic and cell type adjustedModel 4,
demographic, cell type, and abdominal obesity
Model 5, demographic, cell type, and obesity

All races
 All sexes1.87 (1.19–2.94)
(n = 7049)
1.09 (0.651.85)
(n = 6127)
1.14 (0.671.94)
(n = 6115)
1.13 (0.482.65)
(n = 2829)
1.17 (0.522.62)
(n = 3373)
 Male2.95 (1.43–6.09)
(n = 3621)
1.13 (0.492.61)
(n = 3195)
1.12 (0.502.52)
(n = 3191)
0.98 (0.293.24)
(n = 1607)
1.32 (0.424.17)
(n = 1886)
 Female1.25 (0.712.20)
(n = 3428)
0.91 (0.421.98)
(n = 2932)
0.99 (0.442.22)
(n = 2924)
1.087 (0.293.93)
(n = 1222)
0.72 (0.202.57)
(n = 1487)
Other Hispanic
 All sexes5.03 (1.05–24.13)
(n = 312)
4.09 (0.5431.18)
(n = 269)
1.72 (0.1519.44)
(n = 268)
0.74 (0.086.94)
(n = 128)
15.20 (0.27860.28)
(n = 160)
 Male17.00 (1.67–173.24)
(n = 137)
0.52 (0.00834.10)
(n = 126)
0.06 (0.00057.80)
(n = 125)
 Female1.86 (0.2712.75)
(n = 175)
22.51 (0.63807.0)
(n = 143)
37.14 (0.652109.41)
(n = 143)
African-American
 All2.43 (0.866.86)
(n = 1445)
1.86 (0.585.99)
(n = 1190)
1.84 (0.645.18)
(n = 1189)
2.09 (0.656.70)
(n = 479)
3.23 (0.7014.90)
(n = 574)
 Male5.52 (1.38–22.10)
(n = 696)
3.53 (0.7915.73)
(n = 567)
4.98 (1.03–24.13)
(n = 566)
5.56 (0.16192.8)
(n = 291)
5.84 (0.29119.55)
(n = 315)
 Female1.34 (0.325.0)
n = 749
1.46 (0.277.75)
(n = 623)
1.28 (0.354.70)
(n = 623)
2.25 (0.1242.06)
(n = 188)
2.33 (0.1732.77)
(n = 259)
Mexican-American
 All0.65 (0.311.35)
(n = 1201)
0.39 (0.141.09)
(n = 1007)
0.41 (0.151.16)
(n = 1001)
0.37 (0.091.52)
(n = 537)
0.15 (0.03–0.64)
(n = 594)
 Male0.46 (0.191.11)
(n = 537)
0.23 (0.051.04)
(n = 471)
0.22 (0.041.03)
(n = 470)
0.07 (.006–0.79)
(n = 284)
0.012 (0.0006–0.24)
(n = 296)
 Female1.10 (0.196.38)
(n = 664)
1.03 (0.138.36)
n = 536
1.59 (0.2211.54)
(n = 531)
6.00 (0.19188.15)
(n = 253)
0.48 (0.045.38)
(n = 298)
Non-Hispanic White
 All1.93 (1.07–3.49)
(n = 3894)
1.136 (0.622.07)
(n = 3487)
1.20 (0.662.18)
(n = 3483)
0.98 (0.372.55)
(n = 1589)
0.99 (0.332.97)
(n = 1936)
 Male3.01 (1.32–6.91)
n = (2172)
1.22 (0.502.96)
n = 1959
1.31 (0.543.16)
(n = 1958)
0.98 (0.2653.82)
(n = 934)
1.38 (0.365.73)
(n = 1146)
 Female1.29 (0.562.97)
n = (1722)
0.82 (0.322.08)
n = 1528
0.87 (0.352.16)
(n = 1525)
0.44 (0.111.91)
(n = 655)
0.37 (0.071.90)
(n = 790)
Others/mixed race
 All0.14 (0.02–0.92)
(n = 197)
0.00004 (0.000000001–0.14)
(n = 174)
1.00e − 0.06 (2.59e − 11–0.04)
(n = 174)
1.97e − 24 (1.97e − 14–0.18)
(n = 96)
 Male0.01 (0.000033.28)
n = (79)
0.00002 (1.62e − 09–0.18)
n = 72
5.03e − 16 (8.76e – 45 − 2.90 + 13) 
(n = 72)
 Female0.26 (0.041.64)
n = (118)
2.85e − 0.08 (1.61e − 17–50.50) 
(n = 102)
8.46e − 08 (4.25e − 14–0.17)
(n = 102)

Model 1 does not adjust for any covariates. Model 2 adjusts for the following control variables: foreign birthplace, education (less than high school, high school diploma, and more than high school), married and age (as continuous), age squared, and poverty to income ratio. Model 3 adjusts for all the variables in model 2 in addition to cell type composition, blood cells (SI), lymphocytes (%), monocytes (%), platelets (%), basophils (%), eosinophils (%), and neutrophils (%). Model 4 includes all the variables in model 3 and additionally includes abdominal obesity as an outcome (in addition to elevated ALT). Model 5 adjusts for all the variables in model 2 in addition to adding obesity as an outcome (in addition to elevated ALT). Note. ;

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.